| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-06T02:42:47Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; Chang K.-J.; Chang C.-C.; Yu Y.-H.; LIAN-YU LIN; Hwang J.-J. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-12T06:27:51Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; KING-JEN CHANG; Chang C.-C.; Yu Y.-H.; Lin L.-Y.; Hwang J.-J. |
| 臺大學術典藏 |
2022-06-10T06:11:05Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-05-09T08:46:35Z |
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal disease
|
Chao C.-T.; YEN-CHING CHEN; Chiang C.-K.; Huang J.-W.; Hu F.-C.; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-05-09T08:46:33Z |
Interplay between Superoxide Dismutase, Glutathione Peroxidase, and Peroxisome Proliferator Activated Receptor Gamma Polymorphisms on the Risk of End-Stage Renal Disease among Han Chinese Patients
|
Chao C.-T.; YEN-CHING CHEN; Chiang C.-K.; Huang J.-W.; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-05-09T08:46:30Z |
Effect of Kidney Dysfunction on Cerebral Cortical Thinning in Elderly Population
|
Chen C.-H.; Chen Y.-F.; Chiu M.-J.; Chen T.-F.; Tsai P.-H.; Chen J.-H.; Yen C.-J.; Tang S.-C.; Yeh S.-J.; YEN-CHING CHEN |
| 臺大學術典藏 |
2022-05-09T08:46:30Z |
Diabetes mellitus, superoxide dismutase and peroxisome proliferator activated receptor gamma polymorphisms modify the outcome of end-stage renal disease patients of Han Chinese origin
|
Chao C.-T.; Huang J.-W.; Chiang C.-K.; YEN-CHING CHEN; Fang C.-C.; Hu F.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-04-26T01:30:37Z |
The effects of measurement site and ambient temperature on body temperature values in healthy older adults: A cross-sectional comparative study
|
Lu S.-H.; YU-TZU DAI; Yen C.-J. |
| 臺大學術典藏 |
2022-04-26T01:30:35Z |
Shared risk factors for distinct geriatric syndromes in older Taiwanese inpatients
|
Chen C.C.-H.; YU-TZU DAI; Yen C.-J.; Huang G.-H.; Wang C. |
| 臺大學術典藏 |
2022-04-26T01:30:34Z |
Prevalence of geriatric conditions: A hospital-wide survey of 455 geriatric inpatients in a tertiary medical center
|
Chen C.C.H.; Yen C.-J.; YU-TZU DAI; Wang C.; Huang G.-H. |
| 臺大學術典藏 |
2022-04-26T01:30:32Z |
Effect of age on febrile response in patients with healthcare-associated bloodstream infection
|
Lu S.-H.; Chen Y.-C.; Chang Y.-C.; Yen C.-J.; YU-TZU DAI |
| 臺大學術典藏 |
2022-04-15T06:39:33Z |
Shared risk factors for distinct geriatric syndromes in older Taiwanese inpatients
|
CHERYL CHIA-HUI CHEN; Dai Y.-T.; Yen C.-J.; Huang G.-H.; Wang C. |
| 臺大學術典藏 |
2022-04-15T06:39:32Z |
Modified hospital elder life program: Effects on abdominal surgery patients
|
CHERYL CHIA-HUI CHEN; Lin M.-T.; Tien Y.-W.; Yen C.-J.; Huang G.-H.; Inouye S.K. |
| 臺大學術典藏 |
2022-04-15T06:39:31Z |
Prevalence of geriatric conditions: A hospital-wide survey of 455 geriatric inpatients in a tertiary medical center
|
CHERYL CHIA-HUI CHEN; Yen C.-J.; Dai Y.-T.; Wang C.; Huang G.-H. |
| 臺大學術典藏 |
2022-04-15T06:39:26Z |
Pre-surgical Geriatric Syndromes, Frailty, and Risks for Postoperative Delirium in Older Patients Undergoing Gastrointestinal Surgery: Prevalence and Red Flags
|
CHERYL CHIA-HUI CHEN; Lin M.-T.; Liang J.-T.; Chen C.-M.; Yen C.-J.; Huang G.-H. |
| 臺大學術典藏 |
2022-03-31T02:39:37Z |
Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients
|
Kao T.-W.; Huang J.-W.; Hung K.-Y.; Chang Y.-Y.; PAU-CHUNG CHEN; Yen C.-J.; Chen Y.-M.; Chu T.-S.; Wu M.-S.; Tsai T.-J.; Wu K.-D.; Wang J.-D. |
